Clinical Trials · NCT06726577
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
- Phase
- Phase 1/Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Talengen Institute of Life Sciences, Shenzhen, P.R. China.
- Enrollment
- 60
- Start date
- May 2026
- Locations
- 1 site, China
- Primary endpoint
- Amyotrophic Lateral Sclerosis Rating Scale (ALSFRS-R)